Monitoring antigenemia is useful in guid
β
A. P. Berg; A. M. Tegzess; A. Scholten-Sampson; J. Schirm; M. Giessen; T. H. The
π
Article
π
1992
π
Springer
π
English
β 701 KB
We investigated the value of monitoring CMV antigenemia during and after antiviral therapy for CMV disease. During the study period, 10 out of 214 renal transplant recipients were treated for CMV disease, receiving a total of 14 courses of treatment. Antigenemia decreased within 7 days after onset o